Introduction
Vagus nerve stimulation (VNS) is an established and safe therapy for people with refractory epilepsy leading to a significant improvement of seizure control in a considerable proportion of the implanted patients [1] [2] [3] . A novel VNS device was recently approved in Europe, which rapidly detects increases in heart rates (HR) and applies an additional stimulus if the HR-increase exceeds a given threshold (AspireSR TM generator, Cyberonics Inc., Houston, USA). Given that the majority of focal seizures are associated with an increase in HR and only a minority with no apparent change or a decrease in HR [4] [5] [6] , many patients could potentially benefit from the use of this novel device. Importantly, some patients and relatives have reported an attenuation or shortening of seizures due to additional magnet vagus nerve stimulation [7, 8] . To date, however, the effects of such HR-triggered VNS-pulses on the duration and severity of seizures have not been studied under controlled conditions. Here we report on a patient with refractory epilepsy who was recently implanted with such a novel VNS device at our centre.
Methods

Heart rate device setting
Pre-surgical electrocardiogram (ECG; Schiller, Ottobrunn, Germany) was performed 24 h before surgery following the manufacturer's protocol for the AspireSR TM generator (Cyberonics Inc., Houston, USA) in order to determine the patient's heart vector in seven different body positions. To increase the HR-detection sensitivity, at least four representative R-waves were measured from peak to peak in each body position and the R-wave with the minimal amplitude was chosen. According to the manufacturer's protocol, a median of 0.8 mV determined of the seven minimum Rwaves was used for the HR detection setting and the third sensitivity level was applied when R-wave amplitudes were measured between 0.71 and 0.85 mV. During the entire video-EEG monitoring, the VNS-detection device was switched on and the threshold kept unchanged in all conditions. The heart beat sensitivity threshold of 50% was chosen, because HR increased by at least 57% during five habitual seizures recorded during a diagnostic video-EEG monitoring 2 years prior to VNS-implantation.
Video-EEG-monitoring and determination of seizure duration
One day after VNS-implantation, the patient underwent video-EEG monitoring (Micromed S.p.A, Mogliano Veneto, Italy) with the help of scalp EEG according to the 10/20 system for 68 h without changes of anticonvulsant drugs (Fig. 1A) . The device tablet was synchronised with the time of the video-EEG system. The patient complied with the following procedure: no regular cyclic VNS-stimuli during the first 22 h (control condition). During this period, the VNS-device only detected HR-increases and eventually applied a sham-stimulation (stimulus at 0.125 mA with a pulse width of 500 ms at a frequency of 30 Hz for 60 s). After these 22 h, cyclic regular VNS-stimulation was initiated up to 2 mA (which was very well tolerated) on days 2-4 (Fig. 1A) . The cardiac-based and seizure-related extra-stimulus was also set to 2 mA. Finally, the patient underwent another 46 h of video-EEGmonitoring on days 5 and 6 (Fig. 1A) . During this phase, the cycle stimulation was set to 0 mA with a stimulus duration of 7 s, a pulse width of 500 ms and off-time of 180 min (thus no regular cyclic VNS stimulation), whereas the HR-triggered VNS-stimulus was set to 2 mA (stimulus duration 60 s, pulse width 250 ms). Seizure duration was determined by two epileptologists (KGH, RS) based on clinical features and blinded to the sham-stimulation period (control) or active HR-triggered VNS stimulation period (the ictal EEG pattern was commonly compromised by movement artefacts and therefore it was less precise to determine seizure duration based on ictal EEG pattern than on clinical features). The remaining seizure duration after the onset of the HR-triggered VNS-stimulation was measured by subtracting the latency between seizure onset and start of the HR-triggered VNS-stimulus from the total seizure duration.
Statistical measures
The novel VNS-device detects events with HR-increases exceeding a given threshold and stores date, time and whether VNS-stimulation was performed in response to the event. Only those events during which the VNS-device has delivered an extrastimulus were considered as a seizure detected by the device. According to the manufacturer, the device does not stimulate in the following circumstances: (1) The HR-increase lasts less than 1 s. (2) HR-triggered stimulation was set to 0 mA or seizure detection was switched off. (3) Seizure detection is switched ''on'', but the stimulation is prevented by an internal algorithm (the socalled ''Enforced-Off-Time'' which lasts for at least 30 s up to a duration as long as the HR-triggered stimulation).
The sensitivity of the VNS-device was determined by dividing the number of correctly detected seizures (true positives as assessed by video-EEG monitoring) by the sum of the number of correctly detected seizure and the number of non-detected seizures (false negatives). The positive predictive value (PPV) was calculated by dividing the number of true positives by the sum of the number of true positives and the number of events the device wrongly classified as seizures (false positives). The specificity was determined by dividing the number of correctly detected non-seizure events with increased HR (true negatives) by the number of total non-seizure events with increased HR. The negative predictive value (NPV) was calculated by dividing the number of true negatives by the sum of the number of true negatives and the number of false negatives.
The Shapiro-Wilk test and normal probability plot was used to test for normality (Rstudio version 0.98.507, FOAS, Boston, USA). Two-sided unpaired Student's t-test was performed to compare seizure duration during sham-stimulation (control condition) and HR-triggered VNS-stimulation (test condition) (GraphPad Prism 6, GraphPad Software, San Diego, USA). 
Results
Case presentation
A 29-years old male patient with refractory epilepsy since early childhood was referred for presurgical non-invasive assessment. At admission, he reported having 2-5 focal seizures per 24 h that usually occurred during sleep. On awakening, he felt a sensory aura in the left arm followed by bizarre movements. The neurological and clinical examinations were normal. Magnetic resonance imaging (MRI) demonstrated a focal cortical dysplasia (FCD) in the right central region including the pre-and postcentral gyrus ( Fig. 2A and B) . Interictal scalp EEG consistently showed spikes and polyspikes over the central region (Fig. 2C) . Video-EEG monitoring confirmed stereotypical sensory-motor seizures consisting of tonic contraction of the left limbs followed by hyperkinetic movements, postures and sometimes unformed vocalisation. The ictal EEG displayed an arousal pattern followed by generalised EEG flattening and muscle artefacts, the concomitant one-lead ECG revealed a prominent HR-increase of 57% or more as compared to the preictal baseline (mean absolute ictal HR-increase 40 AE 8.2 bpm). Due to the localisation of the lesion in eloquent areas, resective epilepsy surgery was not recommended. In view of the prominent ictal HR-increase, we offered the implantation of an AspireSR TM VNS-device instead. After VNS-implantation, video-EEG monitoring was performed to evaluate the effects of HR-triggered VNS-stimulation on seizure properties.
VNS-based seizure counting
After VNS-implantation, 12 stereotypical seizures with tonic contraction of the left limbs followed by hyperkinetic movements and postures were captured. In the control condition, five seizures with sham-stimulation and one seizure without sham-stimulation were recorded. In the test condition, six seizures with active HRtriggered VNS-stimulation were captured during the video-EEG monitoring. In 11 of 12 seizures, HR increased by at least 56% as compared to preictal baseline (mean absolute HR-increase 44.2 AE 9.8 bpm) (simultaneous one-lead ECG could not be analysed in one seizure due to movements artefacts), which was similar to the seizures recorded two years prior to VNS-implantation.
The VNS-device detected a total of 160 events of which 21 were not classified as seizures (see supplementary Table 1 ). One of the 21 events was in fact an epileptic seizure with an associated HRincrease of 78% (confirmed by video-EEG telemetry and simultaneous one-lead ECG), which means that 20 events were correctly identified as non-seizure related events (specificity 13.5%, NPV 95.2%). One hundred thirty-nine events were recognised as a seizure by the VNS-device. Eleven of the 12 seizures were correctly identified as a seizure, whereas 128 events were not seizure-related as assessed by video-EEG-monitoring (sensitivity 92%, PPV 8%).
Supplementary Table 1 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.seizure.2015.02. 004.
The mean time delay between the clinical seizure onset and detection by the device was 7.4 AE 5 s. The HR-triggered VNSstimulation significantly reduced the total seizure duration by 20% from 33.2 AE 4.8 s to 26.5 AE 5.0 s (p = 0.039, control condition and test condition n = 6) (Fig. 1B) and the remaining seizure duration after the onset of the extra-stimulation by 40% from 27.8 AE 4.3 s to 16.2 AE 3.2 s (p = 0.001, control condition n = 5, test condition n = 6) (Fig. 1C) . No seizure was immediately stopped at the onset of HRtriggered VNS-stimulation. Interestingly, the patient himself also noticed a reduction of the seizure duration at his last follow-up 3 months after implantation of the VNS-device upon a combination of cyclic and HR-triggered VNS stimulation. Seizure frequency was also remarkably reduced, since he reported 2 of 7 days without seizures, whereas before VNS-implantation, he has suffered from seizures every day. 
Discussion
Our case illustrates that additional VNS-stimulation in response to seizure-related HR-increases is able to significantly reduce seizure duration. Furthermore, our data highlights the high sensitivity, but low specificity of the novel VNS-device to detect seizures with associated HR-increases. To the best of our knowledge, this is the first study that evaluated the effect of seizure-related VNS-pulses on seizure duration in humans under controlled conditions. In previous studies, the evaluation of effects of on demand VNS stimulation was restricted to historical controls or subjective reports given by patients and caregivers about VNSstimulation from magnet activation [9] . The few studies that used EEG recordings as an objective measurement are mostly in the interictal period [10, 11] . In one study, an additional VNSstimulation by magnet activation appeared to promptly stop the ongoing seizure, as captured during a video-EEG-monitoring [12] . In our patient, none of the six seizures was terminated by the HRtriggered VNS-pulse, but significantly shortened. Our findings support reports of patient and caregivers about seizure shortening due to magnet VNS pulses [7, 8] . However, some patients are not able to use the magnet properly and caregivers are not always around when seizures occur [9] . These patients may potentially benefit from automatically triggered VNS-stimulation.
The individual configuration of the novel VNS-device in our patient resulted in a high sensitivity of seizure detection and a high NPV. In contrast, specificity and PPV were low. As the HR-threshold is adaptable, these values are likely to change given individual circumstances. For example increasing the HR-threshold from 50 to 60% may increase PPV and specificity, whereas sensitivity and NPV may decrease (some seizures had an HR-increase below 60% and might not have been detected). Since these features vary greatly between individuals, no generalisable conclusions regarding sensitivity, specificity, PPV and NPV of the device can be drawn from one patient [13] . This case indicates, however, the difficulties of automatic seizure detection using a single parameter [14] . The VNS-device has failed to detect one epileptic seizure in our patient, because it was already activated by a preceding HR-increase caused by a sleep arousal 107 s before the seizure onset (confirmed by video-EEG telemetry). Therefore, the VNS-device was unable to stimulate (Enforced-Off-Time, see Section 2). An alternative explanation could be that the preceding sleep arousal was in fact a true epileptic seizure which was terminated by HR-triggered stimulation. Given the fact that the responsive VNS-stimulation was applied in average 7.4 s after the clinical seizure-onset, however, it is rather unlikely that the seizure was terminated before the onset of typical clinical symptoms. Moreover, the distribution of the events recorded by the VNS-device showed a circadian pattern with a peak during night and in the early morning (see supplementary Fig. 1) , suggesting that the detected cardiac events are most probably due to frequent physiological arousals during sleep [15] .
Supplementary Fig. 1 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.seizure.2015.02.004.
There are two major limitations of our study that need to be critically discussed. Firstly, the lack of randomisation of VNS stimulation may impair the validity of our results to some extent. Randomisation was difficult to realise because of the technical restrictions of the VNS-device configuration (e.g. it was impossible to set the device to an alternating one-to-one sham-and activestimulation). Therefore, instead of randomisation we controlled for known confounders (e.g. we kept anticonvulsant drugs unchanged during the observation period; cyclic VNS-stimulation was not applied during the video-EEG monitoring). In this context, it is important to note that we do not know the variability of seizure duration from day-to-day or after longer time periods. For instance in our patient, the mean seizure duration 2 years prior to VNSimplantation amounted to about 25 s under the same anticonvulsant drug regime, which is shorter than that of the seizures recorded 1 day after VNS implantation with sham-stimulation. To estimate the day-to-day variability, we have randomly selected one patient with frequent hyperkinetic seizures and determined the seizure duration for several days without significant differences (see supplementary Fig. 2 ), strengthening our hypothesis of a VNS-induced shortening of seizure duration. Secondly, we have analysed data of one patient only. The strength of our study, however, is the relatively high number of recorded seizures under video-EEG surveillance, providing the true number and the clinical features of the epileptic seizures. Supplementary Fig. 2 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.seizure.2015.02.004.
The exact mechanisms of how VNS exerts its anticonvulsant effects are still unknown [1, 16] , but the modulation of cortical excitability through thalamocortical projections as a result of the stimulation of the vagus nerve is thought to play a role [17, 18] . At least in the interictal period, however, no apparent effects on EEG occurred during vagus nerve stimulation [10, 11] . One may speculate that the observed clinical effects on seizures are not specific to the simulation of the vagus nerve, but are rather unspecific, e.g. due to activation of the arousal system.
In conclusion, our case provides evidence that additional VNSstimulation in response to seizure-related HR-increases is able to significantly reduce seizure duration. From a clinical point of view, a significant reduction of seizure duration may protect patients from the potential harm of prolonged seizures and maybe from evolution into generalised convulsive seizures [19] . Despite the limitations of our report, this promising result prompts larger studies to confirm the clinical benefit of this novel VNS-device.
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